Trial reportScientific reports2026
Neurofilament light chain dynamics following ischemic stroke and their modulation by transauricular vagus nerve stimulation.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05390580 (Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemic stroke is a leading cause of death and disability worldwide. Although advances in interventions for acute ischemic stroke (AIS) restore blood flow to ischemic tissue, neuronal injury continues to evolve following recanalization. There is a critical need to develop interventions that can attenuate this progressive injury. This study investigated plasma neurofilament light chain (NfL) as a marker of neuroaxonal damage after AIS. In a prospective, randomized, open-label, blinded-endpoint, sham-controlled trial, 35 AIS patients received twice-daily taVNS or sham stimulation for five days or until discharge. We measured NfL at four time points after last known normal (LKN): Days 0 (within 24 h), 1, 3, and 5. We evaluated whether transauricular vagus nerve stimulation (taVNS) modulates its dynamics after AIS. Plasma NfL level continued to increase during the acute and early subacute periods following AIS. Higher NfL levels predicted poorer modified Rankin Scale scores at day 90. We identified factors that affect NfL levels, including imaging-based measures of cerebral edema and infarct volume, race, IL-10 at admission, and thrombolytic treatment. After regressing NfL on the identified factors, treatment assignment was not significantly associated with overall NfL levels. Nevertheless, NfL-trajectory modeling suggested that taVNS was associated with a less pronounced rise in NfL after AIS and with significantly lower NfL levels on Days 3 and 5 after LKN, compared with sham stimulation. Our findings inform the clinical use of NfL as a biomarker of long-term functional recovery after AIS and warrant evaluation in larger and longer trials to determine whether taVNS can meaningfully mitigate neuroaxonal injury after AIS.Trial registration: NCT05390580, https://clinicaltrials.gov/study/NCT05390580-Study started/registered: 26/09/2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.